<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2415">
  <stage>Registered</stage>
  <submitdate>1/07/2009</submitdate>
  <approvaldate>1/07/2009</approvaldate>
  <nctid>NCT00931463</nctid>
  <trial_identification>
    <studytitle>A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen</studytitle>
    <scientifictitle>A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy</scientifictitle>
    <utrn />
    <trialacronym>SECOND-LINE</trialacronym>
    <secondaryid>SECOND-LINE</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - raltegravir
Treatment: drugs - 2N(t)RTI
Treatment: drugs - Ritonavir-boosted lopinavir

Active Comparator: Ritonavir-boosted lopinavir and 2N(t)RTI - This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.

Experimental: Ritonavir-boosted lopinavir and raltegravir - This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.


Treatment: drugs: raltegravir
400 mg raltegravir tablet taken every 12 hours

Treatment: drugs: 2N(t)RTI
2N(t)RTIs as prescribed

Treatment: drugs: Ritonavir-boosted lopinavir
2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization</outcome>
      <timepoint>48 weeks following randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population - The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Non-completer Classed as Failure - The non-completer classed as failure analysis will include all randomised participants; participants who meet the following criteria will be defined as failures:
i. week 48 HIV RNA being above each threshold ii. has missing HIV-1 RNA data for any reason iii. stops randomly assigned therapy</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Baseline VL &gt;100,000 Copies Per mL - The difference between treatment arms in proportion of participants with plasma HIV RNA &lt; 200 copies/mL 48 weeks after randomization, per-protocol population: stratified analysis by baseline plasma viral load (less than or equal to 100,000 copies per mL or &gt;100,000 copies per mL) on those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, VL Less Than or Equal to 100,000 Copies Per mL - The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. HIV-1 positive by licensed diagnostic test

          2. Aged 16 years or older (or minimum age as determined by local regulations or as legal
             requirements dictate)

          3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for
             at least 24 weeks

          4. No change in antiretroviral therapy within 12 weeks prior to screening

          5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological
             criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater
             then 500 copies/mL

          6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase
             inhibitors

          7. Able to provide written informed consent</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. The following laboratory variables:

               -  absolute neutrophil count (ANC) &lt; 500 cells/microlitres

               -  hemoglobin &lt; 7.0 g/decilitres

               -  platelet count &lt; 50,000 cells/microlitres

               -  ALT great than 5 x ULN

          2. Pregnant or nursing mothers

          3. Participants with active viral hepatitis B infection defined by the presence in serum
             of hepatitis B surface antigen

          4. Use of immunomodulators within 30 days prior to screening

          5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride,
             pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine,
             astemizole, terfenadine, vardenafil, and St. John's wort)

          6. Intercurrent illness requiring hospitalization

          7. Active opportunistic disease not under adequate control in the opinion of the site
             Principal Investigator

          8. Participants with current alcohol or illicit substance abuse that in the opinion of
             the site Principal Investigator might adversely affect participation in the study

          9. Participants deemed by the site Principal Investigator unlikely to be able to remain
             in follow-up for the protocol-defined period</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>558</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Albion Street Centre - Sydney</hospital>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Centre Clinic - Melbourne</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3182 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mar del Plata Provincia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario Provincia de Sante Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico D.F.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Nigeria</country>
      <state>Plateau State</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Soweto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Abbott</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>amfAR, The Foundation for AIDS Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI
      regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and
      2N(T)RTIs will offer comparable efficacy to that provided by ritonavir-boosted lopinavir and
      raltegravir.

      The study will be conducted for 96-weeks with the primary endpoint analyzed after 48-weeks.

      The primary endpoint is virological: a comparison of virological suppression in plasma &lt; 200
      copies/mL between the randomized arms after 48 weeks.

      Secondary and exploratory endpoints include virological, immunological, safety, clinical,
      metabolic, drug adherence, drug resistance and quality of life.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00931463</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David A Cooper, MD</name>
      <address>Kirby Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>